
Commentary|Podcasts|November 18, 2025
Inside AHA’s Late-Breaking Lipid Trials: The Rise of Oral PCSK9 Inhibition
Fact checked by: Ron Panarotti
Advertisement
This week, host Craig Beavers spoke with Joe Saseen, PharmD, BCPS, BCACP, CLS, about several key trials presented at the American Heart Association 2025 Scientific Sessions.
Show notes:
- VESALIUS-CV trial:
https://www.nejm.org/doi/full/10.1056/NEJMoa2514428 CORAL REEF trial
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib
2
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
3
A Supplemental Blood Test to Bridge Gaps in Breast Cancer Screening Access
4
AI-Powered Deep Proteomics Enables Early, Non-Imaging Detection of Breast Cancer With MRI-Comparable Accuracy
5




















































































































































































































